2. Search Result
Search Result
Results for "

[Ca2 ]i

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

11

Peptides

11

Natural
Products

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136460
    Calcium ionophore I

    ETH 1001

    		 Calcium Channel Others
    Calcium ionophore I (ETH 1001) is a selective Ca 2+ ionophore for biological membranes. Calcium ionophore I can be used in Ca2+-selective microelectrodes that can be used for quantitative intracellular measurements of resting Ca2+-activities and of slowly changing Ca2+-levels .
    Calcium ionophore I
  • HY-A0236A
    Aprindine hydrochloride

    		Potassium Channel Cardiovascular Disease
    Aprindine hydrochloride is a class I-b anti-arrhythmic agent and a hERG channel blocker with an IC50 of 0.23 μM. Aprindine hydrochloride has inhibitory effects on Na+/Ca2+ exchanger currents, which is partly responsible for their antiarrhythmic and cardioprotective effects. Aprindine hydrochloride is widely used for trial and ventricular tachyarrhythmias research research.
    Aprindine hydrochloride
  • HY-16952A
    Bepridil hydrochloride hydrate
    5 Publications Verification

    (±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate

    		 Calcium Channel Cardiovascular Disease
    Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca + channel antagonist and Na +, K + channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac Na +/Ca2 + exchange (NCX1) inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders .
    Bepridil hydrochloride hydrate
  • HY-113970A
    Nebracetam hydrochloride

    WEB 1881 FU hydrochloride

    		 mAChR Neurological Disease
    Nebracetam hydrochloride, a nootropic M1-muscarinic agonist, induces a rise of intracellular Ca 2+ concentration. Nebracetam hydrochloride exhibits an EC50 of 1.59 mM for elevating [Ca 2+]i .
    Nebracetam hydrochloride
  • HY-75161R
    (-)-Menthol (Standard)

    		TRP Channel Endogenous Metabolite Cancer
    (-)-Menthol (Standard) is the analytical standard of (-)-Menthol. This product is intended for research and analytical applications. (-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca2+-permeable nonselective cation channel, to increase [Ca2+]i . Antitumor activity .
    (-)-Menthol (Standard)
  • HY-132190
    Hexanolamino PAF C-16

    1-O-Hexa-decyl-2-acetyl-sn-glycero-3-phospho(N,N,N-trimethyl)-hexanolamine

    		 Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca 2+-dependent and -independent pathways. Related to platelet aggregation .
    Hexanolamino PAF C-16
  • HY-P5189A
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA

    		Endogenous Metabolite Cholinesterase (ChE) Others
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels .
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA
  • HY-118148
    UK-66914

    		Potassium Channel Cardiovascular Disease
    UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents .
    UK-66914
  • HY-N1584BR
    Halofuginone hydrochloride (Standard)

    		Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (hydrochloride) (Standard) is the analytical standard of Halofuginone (hydrochloride). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects [4] .
    Halofuginone hydrochloride (Standard)
  • HY-103660
    18:0 LYSO-PE

    		Liposome Neurological Disease
    18:0 LYSO-PE is a lysophospholipid that can induce [Ca 2+]i increase.
    18:0 LYSO-PE
  • HY-P1075
    CALP3
    2 Publications Verification

    		 Calcium Channel Neurological Disease Cancer
    CALP3, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3
  • HY-P1075A
    CALP3 TFA

    		Calcium Channel Neurological Disease Cancer
    CALP3 TFA, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3 TFA
  • HY-75161
    (-)-Menthol
    1 Publications Verification

    		 TRP Channel Endogenous Metabolite Cancer
    (-)-Menthol is a key component of peppermint oil that binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca 2+-permeable nonselective cation channel, to increase [Ca 2+]i . Antitumor activity .
    (-)-Menthol
  • HY-N4237
    Saikogenin D

    		Prostaglandin Receptor Potassium Channel Inflammation/Immunology
    Saikogenin D is isolated from?Bupleurum chinense, has anti-inflammatory effects. Saikogenin D activates epoxygenases that converts arachidonic acid to epoxyeicosanoids and dihydroxyeicosatrienoic acids, and the metabolites secondarily inhibit prostaglandin E2 (PGE2) production. Saikogenin D results in an elevation of [Ca 2+]i due to Ca 2+ release from intracellular stores .
    Saikogenin D
  • HY-W194810
    MCU-i11

    		Mitochondrial Metabolism Neurological Disease Metabolic Disease
    MCU-i11 is a negative regulator of the mitochondrial calcium uniporter (MCU) complex. MCU-i11 can reduce mitochondrial Ca 2+ uptake. MCU-i11 impairs muscle cell growth .
    MCU-i11
  • HY-113920
    Azumolene sodium

    EU4093

    		 Calcium Channel Others
    Azumolene sodium (EU4093) is an analog of Dantrolene (HY-12542) that inhibits malignant hyperthermia (MH) syndrome and intracellular Ca 2+ homeostasis failure caused by Halothane (HY-B1010)/Succinylcholine. Azumolene sodium (0.5-2.0 mg/kg) reduces [Ca 2+]i (from 207 nM to 38 nM) in MH-susceptible skeletal muscle following intramuscular injection .
    Azumolene sodium
  • HY-116723
    CFMMC

    		mGluR Neurological Disease
    CFMMC is a selective allosteric metabotropic glutamate receptor 1 (mGluR1) antagonist. CFMMC inhibits L-glutamate-induced intracellular Ca 2+ mobilization ([Ca 2+]i) in Chinese hamster ovary cells expressing recombinant human mGluR1a with an IC50 value of 50 nM. CFMMC is promising for research of various central nervous system disorders, such as schizophrenia, epilepsy, anxiety, pain, cognitive dysfunction and drug abuse .
    CFMMC
  • HY-N4267
    Yangambin

    		Calcium Channel Infection Cardiovascular Disease
    Yangambin, a furofuran lignan, is already isolated from plants such as member of the Annonaceae family, including species of the genus Rollinia: R. pickeli, R. exalbidaand R. mucosa, as well from the Magnolia biondii. Yangambin, a selective PAF receptor antagonist, inhibits Ca 2+ influx through voltage-gated Ca 2+ channels, leading to the reduction in [Ca 2+]i in vascular smooth muscle cells and consequent peripheral vasodilation . Yangambin exhibits the antiallergic activity against β-hexosaminidase release with an IC50 of 33.8 μM and for anti-inflammatory activity with an IC50 of 37.4 μM .
    Yangambin
  • HY-138620
    MCU-i4
    2 Publications Verification

    		 Mitochondrial Metabolism Metabolic Disease
    MCU-i4 blocks the IP3-dependent mitochondrial Ca 2+-uptake, maintaining the gatekeeping role of their target .
    MCU-i4
  • HY-N9404
    6-Benzoylheteratisine

    		Sodium Channel Neurological Disease
    6-Benzoylheteratisine is an Aconitum alkaloid with potential neuroprotective activity. 6-Benzoylheteratisine can antagonize tetrodotoxin, inhibit the increase of [Na +]i, [Ca 2+]i and glutamate release, and block sodium channels. 6-Benzoylheteratisine has an inhibitory effect on the neuronal activity underlying epileptiform burst discharge .
    6-Benzoylheteratisine
  • HY-N1228
    Soyacerebroside I

    		Others Others
    Soyacerebroside I is a glycosphingolipid, together with Soyacerebroside II, which can be isolated from the seeds of Glycine max Merrill (Leguminosae). Soyacerebroside II shows ionophoretic activity for Ca 2+ .
    Soyacerebroside I
  • HY-P1366
    des-​Gln14-​Ghrelin

    		GHSR Metabolic Disease
    des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
    des-​Gln14-​Ghrelin
  • HY-P1366A
    des-​Gln14-​Ghrelin TFA

    		GHSR Metabolic Disease
    des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
    des-​Gln14-​Ghrelin TFA
  • HY-136190
    TRPC6-PAM-C20

    		TRP Channel Neurological Disease
    TRPC6-PAM-C20 is a selective positive allosteric modulator (PAM) of TRPC6 channels. TRPC6-PAM-C20 is a potent enhancer of channel activation, enabling low basal concentrations of DAG to induce activation of the ion channel. TRPC6-PAM-C20 induces increases in intracellular Ca 2+ concentrations ([Ca 2+]i) in TRPC6-expressing HEK293 cells with an EC50 of 2.37 μM. TRPC6-PAM-C20 can be used as a valuable tool to selectively exaggerate TRPC6-dependent signals .
    TRPC6-PAM-C20
  • HY-131764
    2'-O-MB-cGMP sodium

    2′-O-Monobutyryl-cGMP sodium

    		 Phosphodiesterase (PDE) Others
    2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium is a cyclic GMP-specific phosphodiesterase inhibitor with an I50 value of 35 µM. 2'-O-MB-cGMP (2′-O-Monobutyryl-cGMP) sodium inhibits Ca 2+ dependent phosphodiesterase hydrolysis using cAMP or cGMP as substrate .
    2'-O-MB-cGMP sodium
  • HY-108608
    o-3M3FBS

    		Others Others
    o-3M3FBS is the negative control of m-3M3FBS. o-3M3FBS inhibits inward and outward currents via mechanisms independent of PLC acting in an antagonistic manner. In contrast, o-3M3FBS also causes an increase in [Ca 2+]i in an agonistic manner .
    o-3M3FBS
  • HY-151547
    MRS4719

    		P2X Receptor Neurological Disease
    MRS4719 is a potent P2X4 receptor antagonist with an IC50 value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca 2+]i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .
    MRS4719
  • HY-N4104
    Agaric acid

    Agaricinic Acid

    		 Mitochondrial Metabolism Metabolic Disease
    Agaric acid (Agaricinic Acid) is obtained from various plants of the fungous tribe, i.e. Polyporus officinalis and Polyporus igniarius. Agaric acid induces mitochondrial permeability transition through its interaction with the adenine nucleotide translocase. Agaric acid promotes efflux of accumulated Ca 2+, collapse of transmembrane potential, and mitochondrial swelling. Agaric acid is used to regulate lipid metabolism .
    Agaric acid
  • HY-115864
    Osavampator

    TAK-653; NBI-1065845

    		 iGluR Lipoxygenase Neurological Disease
    Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca 2+ influx in hGluA1i CHO cells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .
    Osavampator
  • HY-P1792
    Angiotensin II (1-4), human

    		Angiotensin Receptor Metabolic Disease Endocrinology
    Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. Angiotensin II also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
    Angiotensin II (1-4), human
  • HY-P1792A
    Angiotensin II (1-4), human TFA

    		Angiotensin Receptor Metabolic Disease Endocrinology
    Angiotensin II (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca 2+ levels. Angiotensin II also acts at the Na +/H + exchanger in the proximal tubules of the kidney .
    Angiotensin II (1-4), human TFA
  • HY-12596
    JNJ-26489112

    		Calcium Channel Sodium Channel Potassium Channel Neurological Disease
    JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures. JNJ-26489112 inhibits voltage-gated Na + channels and N-type Ca 2+ channels, and is effective as a K + channel opener. JNJ-26489112 has very weak inhibition of CA-II (IC50=35 μM) and CA-I (18 μM) .
    JNJ-26489112
  • HY-107678
    SEN12333

    WAY-317538

    		 nAChR Neurological Disease
    SEN 12333 (WAY-317538) is a potent, selective and orally active α7 nAChR agonist. SEN12333 displays high affinity for the rat α7 nAChRs expressed in GH4C1 cells (K>i=260 nM) and acts as full agonist in functional Ca 2+ flux studies (EC50=1.6 μM). SEN 12333 is used for AD and schizophrenia research .
    SEN12333
  • HY-16992A
    W-54011
    5 Publications Verification

    		 Complement System Reactive Oxygen Species Inflammation/Immunology
    W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils with a Ki value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca 2+ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC50s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively .
    W-54011
  • HY-N1584
    Halofuginone
    Maximum Cited Publications
    11 Publications Verification

    RU-19110

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone
  • HY-P1821
    Myelin Basic Protein

    MHP4-14

    		 PKC Neurological Disease
    Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
    Myelin Basic Protein
  • HY-P1821A
    Myelin Basic Protein TFA
    1 Publications Verification

    MHP4-14 TFA

    		 PKC Neurological Disease
    Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
    Myelin Basic Protein TFA
  • HY-N1584C
    Halofuginone lactate

    RU-19110 lactate

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone lactate
  • HY-N1584A
    Halofuginone hydrobromide
    Maximum Cited Publications
    11 Publications Verification

    RU-19110 hydrobromide

    		 DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrobromide
  • HY-N1584B
    Halofuginone hydrochloride

    RU-19110 hydrochloride

    		 Calcium Channel DNA/RNA Synthesis Parasite Sodium Channel TGF-beta/Smad Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrochloride
  • HY-W111226
    Fmoc-His(3-Me)-OH

    		Amyloid-β Amino Acid Derivatives Cardiovascular Disease
    Fmoc-His(3-Me)OH derives Histidine-associating compounds with biological activity. Fmoc-His(3-Me)OH, with Fmoc-citrulline-OH, Fmoc-His(1-Me)-OH together, forms tri-peptides and shows vasodilating effect with EC50s of 2.7-4.7 mM in 1.0 mM Phenylephrine (PE)-contracted aorta rings. Fmoc-His(3-Me)OH (resin) also makes Methyl-His-Gly-Lys (His(3-Me)-Gly-Lys), thus acts as an [Ca 2+]i inhibitor. Fmoc-His(3-Me)OH methylates NAHIS02, making it unable to block the Alzheimer's Aβ channel .
    Fmoc-His(3-Me)-OH
  • HY-P10316
    CaMKI(299-320)

    Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain

    		 CaMK Others
    CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca 2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .
    CaMKI(299-320)
  • HY-N0515
    Ophiopogonin D

    		PPAR NF-κB Calcium Channel Cardiovascular Disease Inflammation/Immunology
    Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside . Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca 2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years .
    Ophiopogonin D
  • HY-N1584AR
    Halofuginone hydrobromide (Standard)

    		DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
    Halofuginone hydrobromide (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: